Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Rheumatology (2022) - Comments
pubmed: 35368384  doi: 10.1016/s2665-9913(22)00044-3  issn: 2665-9913 

MeiLan K Han, Martti Antila, Joachim H Ficker, Ivan Gordeev, Alfredo Guerreros, Amparo Lopez Bernus, Antoine Roquilly, José Sifuentes-Osornio, Fehmi Tabak, Ricardo Teijeiro, Lorraine Bandelli, Diane S Bonagura, Xu Shu, James M Felser, Barbara Knorr, Weihua Cao, Peter Langmuir, Thomas Lehmann, Michael Levine, Sinisa Savic